amurensin G

a SIRT1 inhibitor; structure in first source

Networked: 8 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Benzocycloheptenes
        Dibenzocycloheptenes
        amurensin G: 8
      - Benzene Derivatives: 17
        Phenols: 677
        Resorcinols: 4
        amurensin G: 8
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Benzocycloheptenes
    - Dibenzocycloheptenes
      - amurensin G: 8

Experts

1.	Oh, Won Keun: 6 articles (11/2015 - 11/2010)
2.	Kang, Chi-Dug: 3 articles (11/2015 - 03/2012)
3.	Kim, Sun-Hee: 3 articles (11/2015 - 03/2012)
4.	Dao, Trong Tuan: 3 articles (12/2012 - 11/2010)
5.	Kang, Keon Wook: 3 articles (12/2012 - 11/2010)
6.	Kim, Dong-Wan: 2 articles (11/2015 - 12/2013)
7.	Kim, Hak-Bong: 2 articles (11/2015 - 03/2012)
8.	Lee, Su-Hoon: 2 articles (11/2015 - 12/2013)
9.	Kim, Mi-Ju: 2 articles (12/2013 - 03/2012)
10.	Hien, Tran Thi: 2 articles (12/2012 - 11/2010)

Related Diseases

1.	Colonic Neoplasms (Colon Cancer) 12/01/2013 - "In this study, the sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cytotoxicity and the effect of amurensin G, a novel sirtuin 1 (SIRT1) inhibitor, were examined using the CSC-enriched fraction of HCT-15 human colon cancer cells. "
2.	Neoplasms (Cancer) 11/01/2010 - "amurensin G substantially restored the ability of doxorubicin to inhibit MCF-7/ADR-induced tumor growth. " 02/01/2009 - "Amurensin G (5) and trans-resveratrol (6) showed significant cytotoxic activity against L1210, K562 and HTC116 cancer cell lines with IC(50) values ranging from 15.7 +/- 2.1 to 30.9 +/- 1.8 microM. " 10/01/2012 - "Amurensin G inhibits angiogenesis and tumor growth of tamoxifen-resistant breast cancer via Pin1 inhibition." 12/01/2013 - "Amurensin G enhances the susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity of cancer stem-like cells of HCT-15 cells."
3.	Breast Neoplasms (Breast Cancer) 10/01/2012 - "These results demonstrate for the first time that amurensin G may have therapeutic potential for TAM-resistant breast cancer through blocking of Pin1-mediated VEGF gene transcription." 10/01/2012 - "Amurensin G inhibits angiogenesis and tumor growth of tamoxifen-resistant breast cancer via Pin1 inhibition." 11/03/2015 - "SIRT1 knock-down or SIRT1 inhibitors (amurensin G and EX527) effectively suppressed the resistance to Hsp90 inhibitors (17-AAG and AUY922) in several MDR variants of human lymphoblastic leukemia and human breast cancer cell lines. "
4.	Hypoxia (Hypoxemia) 10/01/2012 - "Molecular analyses using reporter genes with hypoxia response elements and activator protein-1 (AP-1) elements, and western blots revealed that the activities and the nuclear levels of hypoxia inducible factor-1 (HIF-1)α and AP-1 in TAMR-MCF-7 cells were decreased by amurensin G. " 03/01/2012 - "In addition, blockade of SIRT1 activation using siRNA or amurensin G, a new potent SIRT1 inhibitor, abolished hypoxia-induced HIF-1α expression but increased c-Myc and β-catenin expression. "
5.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/03/2015 - "SIRT1 knock-down or SIRT1 inhibitors (amurensin G and EX527) effectively suppressed the resistance to Hsp90 inhibitors (17-AAG and AUY922) in several MDR variants of human lymphoblastic leukemia and human breast cancer cell lines. "

Related Drugs and Biologics

1.	Sirtuin 1
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	Ligands
4.	Catenins
5.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
6.	Small Interfering RNA (siRNA)
7.	Transcription Factor AP-1 (Transcription Factor AP 1)
8.	Tamoxifen
9.	Rotenone
10.	Doxorubicin (Adriamycin)